REFERENCES
- Accera. (2009). Retrieved April 1, 2009, from http://www.accerapharma. com/2009/news34.html.
- Axona Product Bulletin. Retrieved April 1, 2009, from http://www. firstreportnow.com/ProductBulletiGeriatricACCERA.pdf.
- de Leon, M. J., Ferris, S. H., George, A. E., Christman, D. R., Fowler, J. S., Gentes, C., (1983). Positron emission tomographic studies of aging and Alzheimer's disease. American Journal of Neuroradiology, 4(3), 568–571.
- Henderson, S. T., Vogel, J. L., Barr, L. J., Garvin, F., Jones, J. J., & Costantini, L. C. (2009, August 10). Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: A randomized, double-blind, placebo-controlled, multicenter trial. Retrieved March 5, 2010, from Nutrition & Metabolism (London) [online]. doi: 10.1186/1743-7075-6-31. PMCID: PMC2731764.
- Herholz, K., Carter, S. F., & Jones, M. (2007). Positron emission tomography imaging in dementia. British Journal of Radiology, 80(Special issue 2), S160–S167.
- Mosconi, L. (2005). Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease: FDG-PET studies in MCI and AD. European Journal of Nuclear Medicine and Nuclear Imaging, 32(4), 486–510.
- Mosconi, L., Mistur, R., Switalski, R., Tsui, W. H., Glodzik, L., Li, Y. (2009). FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging, 36(5), 811–822.